|
|
||||||||||||||||||||||||||||||||||||
|
Ascendis Pharma A/S (ASND) Ascendis Pharma is a biopharmaceutical company. Co.'s primary investigational product candidate, TransCon Growth Hormone, is in development as a once-weekly prodrug of recombinant human growth hormone as a potential treatment for pediatric growth hormone deficiency. Co. is also using its TransCon technologies to develop other product candidates to address rare endocrine diseases. These product candidates include TransCon Parathyroid Hormone as a potential treatment for adult hypoparathyroidism and TransCon C-Type Natriuretic Peptide as a potential therapeutic option for achondroplasia, the most common form of dwarfism.
|
|
||||||||||||||||||||||||||||||||||||
Free ASND Email Alerts:
Ascendis Pharma A/S (ASND) Page | The Online Investor | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.